A systematic approach to biomarker discovery; Preamble to 'the iSBTc-FDA taskforce on immunotherapy biomarkers'
| Autor: | David F. Stroncek, John M. Kirkwood, A. Karolina Palucka, Yingdong Zhao, Lisa H. Butterfield, Benjamin Zeskind, Samir N. Khleif, Peter P. Lee, Bernard A. Fox, Douglas M. Potter, Giuseppe Masucci, Thomas O. Kleen, Dolores J. Schendel, Mary L. Disis, Magdalena Thurin, Ena Wang, Licia Rivoltini, Sylvia Janetzki, Craig L. Slingluff, Heinz Zwierzina, Madhav V. Dhodapkar, George Coukos, Giorgio Trinchieri, Michele Maio, Antoni Ribas, Francesco M. Marincola, Holden T. Maecker, Xifeng Wu, Mai Britt Zocca, Cristina Maccalli, Jon M. Wigginton, Howard Streicher, Leif Håkansson, Barbara Seliger, Senthamil R. Selvan, Anatoli Malyguine, Damien Chaussabel |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.medical_treatment Best practice Immunology lcsh:Medicine Immune monitoring Medical and Health Sciences Preamble General Biochemistry Genetics and Molecular Biology Education Clinical Research Neoplasms Humans Medicine Biomarker discovery Cancer Clinical Trials as Topic Medical education Natural course United States Food and Drug Administration business.industry Research lcsh:R Reproducibility of Results General Medicine Immunotherapy United States Research Design Commentary business Working group Biomarkers Human cancer Biotechnology |
| Zdroj: | Journal of translational medicine, vol 6, iss 1 Journal of Translational Medicine, Vol 6, Iss 1, p 81 (2008) J. Transl. Med. 6:81 (2008) Journal of Translational Medicine |
| ISSN: | 1479-5876 |
| Popis: | The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|